TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05758259
Drug: oral placebo and basic ingredient placebo topical vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo and basic ingredient placebo topical vitamin D similar to the ointment
Study: NCT00343174
Drug: Ancrod
Normalized name: Ancrod
DrugBank: Ancrod (DB05099)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05641324
Drug: Lenalidomide with low-dose dexamethasone
Normalized name: ethinyl estradiol
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide and dexamethasone administered orally
Study: NCT05641324
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab administered by subcutaneous injection
Study: NCT06238167
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab, 200mg Q3W, max 16 cycles.
Study: NCT06238167
Drug: low dose SOX therapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin: 78mg/m\^2, d1, S-1: 50mg d1-14 bid, followed by 7 days off (Q3W, max 8 cycles).
Study: NCT01112540
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1 mg/kg Intravenous bolus
Study: NCT00002106
Drug: Ranitidine hydrochloride
Normalized name: Ranitidine Hydrochloride
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06276361
Drug: Oral risperidone; QUAR F1/2, Dose 1 - Gluteal
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose level 1
Study: NCT06276361
Drug: Oral risperidone; QUAR F1/2, Dose 3 - Gluteal
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose level 3
Study: NCT06276361
Drug: Oral risperidone; QUAR F1/2, Dose 3 - Deltoids
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose level 3
Study: NCT05651191
Drug: Human CD19 Targeted DASH CAR-T Cells Injection
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous genetically modified anti-CD19 CAR transduced T cells
Study: NCT05957991
Drug: Metformin Hydrochloride tablet
Normalized name: Metformin Hydrochloride Tablets
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment with metformin
Study: NCT05595824
Drug: Molnupiravir (Esperavir)
Normalized name: Molnupiravir
DrugBank: Molnupiravir (DB15661)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Capsules 800 mg, 2 times a day with 12 ±2 hours interval for 5 days
Study: NCT04906980
Drug: JNJ-64281802
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64281802 will be administered orally.
Study: NCT05004116
Drug: Repotrectinib
Normalized name: Repotrectinib
DrugBank: Repotrectinib (DB16826)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPX-0005 (Repotrectinib) will be taken orally twice daily in 28-day cycles without regard to food and will be administered orally before administration of irinotecan and temozolomide (exception: C1, TPX-0005 (Repotrectinib) will be administered once daily x 14 days, then twice daily D15-D28).
Study: NCT05004116
Drug: Irinotecan and temozolomide
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan and temozolomide will be given as per institutional standard.
Study: NCT06400355
Drug: Mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: in which mannitol will be given in doses of 0.5 gm/kg 30 minutes before the end of the surgery
Study: NCT05170594
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab will be administered at 15mg/kg IV, every 3 weeks
Study: NCT05170594
Drug: Fluzoparib
Normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluzoparib will be administered orally continuously at 150mg bid until disease progression and toxicity becomes intolerable
Study: NCT04905121
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin will be provided in form of dry filled capsules and administered orally in three ascending doses
Study: NCT04349774
Drug: Control Group - ESP block with SAP block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: None - Control Group
Study: NCT04349774
Drug: Treatment Group - ESP block with SAP normal saline
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Substitution of normal saline in place of 0.375% Bupivacaine in SAP block
Study: NCT05758298
Drug: NICOTINE 2MG GUM
Normalized name: NICOTINE 2MG GUM
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine 2mg chewing gum in mint flavor (6 pieces of gum per day given, but used as needed).
Study: NCT05758298
Drug: NICOTINE 4MG GUM
Normalized name: NICOTINE 4MG GUM
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine 4mg chewing gum in mint flavor (6 pieces of gum per day given, but used as needed).
Study: NCT05675033
Drug: Serplulimab and Bevacizumab injection
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Serplulimab, 4.5mg/kg, intravenous injection, D1,Q21, until the disease progressed or showed intolerable side effects.~Bevacizumab injection, 7.5mg/kg, intravenous injection, D1, Q21, until the disease progressed or showed intolerable side effects.~Platinum-based chemotherapy: pemetrexed combined with carboplatin, D1-2, Q21, a total of 4 cycles.
Study: NCT05099471
Drug: Venetoclax; Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combination of venetoclax and rituximab
Study: NCT06340633
Drug: Ebselen
Normalized name: Ebselen
DrugBank: Ebselen (DB12610)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutathione peroxidase mimetic
Study: NCT05294055
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide 1.5-1.8g/m2, single dose
Study: NCT05294055
Drug: Mecapegfilgrastim, day 2
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Mecapegfilgrastim 12mg SC, on day 2 after chemotherapy
Study: NCT05294055
Drug: Mecapegfilgrastim, day 5
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Mecapegfilgrastim 12mg SC, on day 5 after chemotherapy
Study: NCT06407180
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: receive intraarticular triamcinolone injection
Study: NCT00446602
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Type=exact, unit=units, number=80,000, form=solution for injection, route=subcutaneous use, once every week or once every 2 weeks.
Study: NCT05331014
Drug: LivaloVA
Normalized name: Livalo
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For 8 weeks(PO, QD)
Study: NCT05331014
Drug: LivaloV
Normalized name: Livalo
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For 8 weeks(PO, QD)
Study: NCT05331014
Drug: VA
Normalized name: Val
DrugBank: Vanillic acid (DB02130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For 8 weeks(PO, QD)
Study: NCT04503460
Drug: Salmeterol Xinafoate
Normalized name: Salmeterol Xinafoate
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All participants will receive inhaled salmeterol xinafoate 50 μg twice in the morning and twice in the evening for 2 weeks; this will be followed by a 2-week washout period during which time no beta-agonists will be administered. Participants will be asked to use 'as required' ipratropium bromide during this period when needed in place of short-acting beta agonists.
Study: NCT06394713
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous administration, 125 mg/m2, d1 and d8, every 3 weeks
Study: NCT06394713
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous administration, 75mg/m2, d1, every 3 weeks
Study: NCT04503460
Drug: Salmeterol Fluticasone
Normalized name: FLUTICASONE/SALMETEROL
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Following the 2-week washout period, all participants will receive inhaled salmeterol xinafoate 50 μg combined with fluticasone propionate 250 μg twice in the morning and twice in the evening for 2 weeks. Participants will be asked to use 'as required' ipratropium bromide during this period when needed in place of short-acting beta agonists.
Study: NCT04704232
Drug: PLAC
Normalized name: placebo
DrugBank: Caplacizumab (DB06081)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Double blind, parallel within subject comparison
Study: NCT04718701
Drug: Anlotinib+Toripalimab+Nab-paclitaxel
Normalized name: Toripalimab
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Using combination treatment of anlotinib (12 mg, po. qd.) plus toripalimab (240 mg, ivgtt. q3w.) and nab-paclitaxel (260 mg/m2, ivgtt, q3w) with every 3 weeks as a cycle.
Study: NCT04766021
Drug: Mirabegron
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose-response effect on thermogenesis
Study: NCT05681507
Drug: Transversus thoracic muscle plane block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound guided bilateral parasternal injection of bupivacain 0.375%, 20ml, at 4th thoracic vertebral level.
Study: NCT05172947
Drug: Resveratrol
Normalized name: Resveratrol
DrugBank: Resveratrol (DB02709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group received resveratrol with the conventional therapy
Study: NCT05169710
Drug: SEP-4199 CR 200 mg
Normalized name: atropine sulfate / benzoic acid / hyoscyamine sulfate / methenamine / methylene blue / phenyl salicylate Oral Tablet [Uri-Sep]
DrugBank: Hyoscyamine (DB00424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEP-4199 CR 200 mg Tablet (supplied in one 200mg tablet and one placebo tablet)
Study: NCT05169710
Drug: SEP-4199 CR 400 mg
Normalized name: atropine sulfate / benzoic acid / hyoscyamine sulfate / methenamine / methylene blue / phenyl salicylate Oral Tablet [Uri-Sep]
DrugBank: Hyoscyamine (DB00424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEP-4199 CR 400 mg tablet (supplied in two 200mg tablets)
Study: NCT05342844
Drug: Dexmedetomidine 0.5 mcg
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.5 mcg/kg
Study: NCT05342844
Drug: Dexmedetomidine 1 mcg
Normalized name: dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mcg/kg
Study: NCT04962022
Drug: PF-07321332/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally every 12 hours for days for a total of 5 doses from Day 1 through Day 3
Study: NCT04962022
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally once daily for 8 days from Days 1 through 8
Study: NCT04962022
Drug: PF-07321332/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally BID for 3 day for a total on 5 doses starting on Day 4 through Day 6
Study: NCT06443151
Drug: Sodium Nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Endothelium-independent vasodilation will be assessed by changes in forearm blood flow in response to intra-arterial infusions of sodium nitroprusside at 1.0, 2.0, 4.0 μg/100 mL forearm tissue/min.
Study: NCT01868048
Drug: Sativex
Normalized name: Castanea sative leaf extract
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Contains delta -9 tetrahydrocannabinol (THC), 27 mg/mL:cannabidiol (CBD), 25 mg/mL, in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring.~Subjects receive study medication delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose is 10 actuations per day. Each actuation delivers THC 2.7 mg and CBD 2.5 mg.
Study: NCT04854837
Drug: Remdesivir
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remdesivir treatment
Study: NCT06558708
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Once daily
Study: NCT06128460
Drug: Zimberelimab
Normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240mg, q3w，8 cycles
Study: NCT06128460
Drug: Platinum
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cisplatin 40mg/m2 for 5-6 cycles
Study: NCT04639180
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive Camrelizumab intravenously, Dosage form: lyophilized powder
Study: NCT04639180
Drug: Rivoceranib (Apatinib)
Normalized name: Rivoceranib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive Rivoceranib (Apatinib) orally, Dosage form: tablet
Study: NCT05458076
Drug: QLS1128 A-Dose 1~5 and Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cohort 1:~QLS1128 A-Dose 1 or Placebo~Cohort 2:~Period 1: QLS1128 A-Dose 2 or Placebo, on day 1. Period 2:QLS1128 A-Dose 2 or Placebo with high fat meal on day 5. Period 3:QLS1128 A-Dose 2 or Placebo plus Ritonavir on day 9~Cohort 3:~QLS1128 A-Dose 3 or Placebo~Cohort 4:~QLS1128 A-Dose 4 or Placebo~Cohort 5:~QLS1128 A-Dose 5 or Placebo
Study: NCT05458076
Drug: QLS1128 C-Dose 1~3 and Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cohort 6:~Period 1: QLS1128 C-Dose 1 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 1 or Placebo plus Ritonavir , twice daily for 7 days~Cohort 7:~Period 1: QLS1128 C-Dose 2 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 2 or Placebo plus Ritonavir , twice daily for 7 days~Cohort 8:~Period 1: QLS1128 C-Dose 3 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 3 or Placebo plus Ritonavir , twice daily for 7 days
Study: NCT05458076
Drug: QLS1128 D-Dose 1 and Ritonavir
Normalized name: lopinavir and ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cohort 9:~Group A:QLS1128 D-Dose 1 plus Ritonavir under fasting condition, on day 1. QLS1128 D-Dose 1 plus Ritonavir under fatty food condition, on day 5~Group B: QLS1128 D-Dose 1 plus Ritonavir under fatty food condition , on day 1. QLS1128 D-Dose 1 plus Ritonavir under fasting condition, on day 5
Study: NCT04952064
Drug: Monosialoganglioside GM1
Normalized name: Monosialoganglioside GM1 antibody
DrugBank: Ganglioside GM1 (DB16948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monosialoganglioside GM1 diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days
Study: NCT05168735
Drug: Intravenous Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)
Study: NCT04360070
Drug: Ketamine Hydrochloride
Normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral General Anesthetic
Study: NCT06364111
Drug: polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in the control group received polyethylene glycol for 6 weeks
Study: NCT03723083
Drug: CC-2001
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-2001 will be administered orally
Study: NCT06168214
Drug: Vonoprazan+amoxicillin+furazolidone 7 days
Normalized name: AMOXICILLIN/VONOPRAZAN
DrugBank: Furazolidone (DB00614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hVAF: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid; F: furazolidone 100mg bid.
Study: NCT06168214
Drug: Vonoprazan+amoxicillin 7 days
Normalized name: AMOXICILLIN/VONOPRAZAN
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hVA7: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid.
Study: NCT06168214
Drug: Vonoprazan+amoxicillin 14 days
Normalized name: vonoprazan
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: hVA14: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid.
Study: NCT05441904
Drug: PXL770
Normalized name: PXL770 free acid anhydrous
DrugBank: PXL-770 free acid anhydrous (DB17615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 500 and 750 mg was administered to each subject.
Study: NCT00002152
Drug: WF10
Normalized name: Sodium hypochlorite
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06216639
Drug: Bismuth Subcitrate
Normalized name: BISMUTH SUBCITRATE
DrugBank: Bismuth subcitrate potassium (DB09275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tripotassium dicitratobismuthate 120 mg film-coated tablets. Prescribed for both primary and (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 120 mg QID for a period of 14 days.
Study: NCT06216639
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazol 40 mg gastro-resistant tablets or hard capsules. Which one of the three brands is prescribed for an individual participant in this prospective study depends on the decision of a chosen personal physician. Prescribed for both primary and (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 40 mg BID for a period of 14 days.
Study: NCT06216639
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazol 400 mg tablets. Prescribed for both primary and (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 400 mg QID for a period of 14 days.
Study: NCT06216639
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 500 mg dispersible tablets or hard capsules. Which one of the two brands is prescribed for an individual participant in this prospective study depends on the decision of a chosen personal physician. Prescribed only for the primary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection who are not allergic to penicillin. The prescribed daily dose is 500 mg QID for a period of 14 days.
Study: NCT06216639
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 500 mg film-coated tablets. Prescribed only for the (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 500 mg OID for a period of 14 days.
Study: NCT05687071
Drug: 180mg of ETC-1002(bempedoic acid)
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180mg, tablet, once daily, for 52 weeks
Study: NCT04543643
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As the third generation of NSBB, carvedilol is more effective in reducing HVPG than propranolol, which is recommended by Baveno VI as the first-line drug for EVB primary prevention.
Study: NCT04543643
Drug: Berberine
Normalized name: berberine
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberine can regulate the intestinal flora, which is safe and effective in clinical application.
Study: NCT06187441
Drug: Daratumumab Injection
Normalized name: daratumumab Injection
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients who have been treated with 12 cycles of Daratumumab-Lenalidomide-Dexamethasone (Dara-Rd) will be randomized between Arm A (continuous therapy) and Arm B (treatment free interval)
Study: NCT06187441
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients who have been treated with 12 cycles of Daratumumab-Lenalidomide-Dexamethasone (Dara-Rd) will be randomized between Arm A (continuous therapy) and Arm B (treatment free interval)
Study: NCT06187441
Drug: Lenalidomide capsule
Normalized name: Lenalidomide Capsules
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients who have been treated with 12 cycles of Daratumumab-Lenalidomide-Dexamethasone (Dara-Rd) will be randomized between Arm A (continuous therapy) and Arm B (treatment free interval)
Study: NCT06009874
Drug: Dapagliflozin 10mg Tab
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: patients will be treated with DAPA 10 mg once daily for three months
Study: NCT05751265
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks . Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
Study: NCT05751265
Drug: Paclitaxel injection
Normalized name: paclitaxel Injection
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive paclitaxel 135 mg/m2 ivgtt q2w or 175mg/m2 q3w
Study: NCT05884320
Drug: Sacituzumab Govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given by IV (vein)
Study: NCT05187208
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Niraparib 200mg or 300mg (once daily \[QD\])\*~\*The recommended starting dosage of niraparib is 200mg QD. For patients who weigh ≥77 kg and have baseline platelet count ≥150,000/μL, the recommended starting dosage is 300 mg QD.
Study: NCT03537807
Drug: Riluzole
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For adult patients, one 40mg of BHV-0223, administered sublingually, on a twice daily basis (approximately every 12 hours).